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CLINICAL AND POPULATION SCIENCES
Cilostazol for Secondary Prevention of Stroke and 
Cognitive Decline
Systematic Review and Meta-Analysis
Caroline McHutchison, MSc; Gordon W. Blair, MRCP; Jason P. Appleton, MCRP, PhD; Francesca M. Chappell, PhD;  
Fergus Doubal, PhD, FRCP; Philip M. Bath, DSc; Joanna M. Wardlaw , MD, FRCR, FRCP
BACKGROUND AND PURPOSE: Cilostazol, a phosphodiesterase 3’ inhibitor, is used in Asia-Pacific countries for stroke prevention, 
but rarely used elsewhere. In addition to weak antiplatelet effects, it stabilizes endothelium, aids myelin repair and astrocyte-
neuron energy transfer in laboratory models, effects that may be beneficial in preventing small vessel disease progression.
METHODS: A systematic review and meta-analysis of unconfounded randomized controlled trials of cilostazol to prevent stroke, 
cognitive decline, or radiological small vessel disease lesion progression. Two reviewers searched for papers (January 1, 
2019 to July 16, 2019) and extracted data. We calculated Peto odds ratios (ORs) and 95% CIs for recurrent ischemic, 
hemorrhagic stroke, death, adverse symptoms, with sensitivity analyses. The review is registered (CRD42018084742).
RESULTS: We included 20 randomized controlled trials (n=10 505), 18 in ischemic stroke (total n=10 449) and 2 in cognitive 
impairment (n=56); most were performed in Asia-Pacific countries. Cilostazol decreased recurrent ischemic stroke (17 
trials, n=10 225, OR=0.68 [95% CI, 0.57–0.81]; P<0.0001), hemorrhagic stroke (16 trials, n=9736, OR=0.43 [95% CI, 
0.29–0.64]; P=0.0001), deaths (OR=0.64 [95% CI, 0.49–0.83], P<0.0009), systemic bleeding (n=8387, OR=0.73 [95% 
CI, 0.54–0.99]; P=0.04), but increased headache and palpitations, compared with placebo, aspirin, or clopidogrel. Cilostazol 
reduced recurrent ischemic stroke more when given long (>6 months) versus short term without increasing hemorrhage, 
and in trials with larger proportions (>40%) of lacunar stroke. Data were insufficient to assess effects on cognition, imaging, 
functional outcomes, or tolerance.
CONCLUSIONS: Cilostazol appears effective for long-term secondary stroke prevention without increasing hemorrhage risk. 
However, most trials related to Asia-Pacific patients and more trials in Western countries should assess its effects on cognitive 
decline, functional outcome, and tolerance, particularly in lacunar stroke and other presentations of small vessel disease.
Key Words: aspirin ◼ cilostazol ◼ clopidogrel ◼ meta-analysis ◼ stroke, lacunar ◼ stroke
Cerebral small vessel disease (SVD) causes 25% of ischemic stroke, most intracerebral hemorrhages, most vascular cognitive impairment and up to 45% 
of dementias, and other important aging-related comor-
bidities.1 There is no specific treatment to prevent SVD 
progression. In a review of SVDs mechanisms and 
therapeutic agents with relevant modes of action,2 we 
identified several licenced drugs including cilostazol, a 
phosphodiesterase 3′ inhibitor. In addition to mild anti-
platelet effects,3 cilostazol has several actions targeting 
processes involved in SVD pathophysiology: endothe-
lial dysfunction, myelin repair, neuroprotection, and 
inflammation.2
Cilostazol is used for stroke prevention in Asia-Pacific 
countries, but in Western countries it is used mostly 
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systematic reviews suggested that cilostazol prevented 
recurrent stroke.4,5 However, further trials have been pub-
lished since the last review, no review has assessed cilo-
stazol’s effects in relevant subgroups and few assessed 
adverse effects (bleeding, headaches, palpitations, etc) 
that could limit cilostazol tolerance.
We performed a systematic review and meta-analysis 
to determine the effect of cilostazol on stroke recur-
rence, cognitive decline, radiological progression of SVD, 
intracerebral hemorrhage, death and adverse symptoms 
in patients with stroke or cognitive presentations of SVD.
METHODS
We published the systematic review protocol on PROSPERO 
(registration No. CRD42018084742) in March 2018 and per-
formed the review according to PRISMA standards.6 The data 
that support the findings of this study are available from the 
corresponding author upon request.
We searched MEDLINE and EMBASE between 1990 and 
July 16, 2019 (Data Supplement) for original articles reporting 
prospective randomized controlled trials of cilostazol in patients 
with stroke, SVD, mild cognitive impairment, or dementia. We 
also searched clinical trial registries (www.isrctn.com; https://
eudract.ema.europa.eu/; www.strokecenter.org/), conference 
proceedings, bibliographies of review papers, previous system-
atic reviews, and trial papers for relevant trials not identified in 
the search, and finally for secondary publications of included 
trials that might provide additional outcomes.
We included randomized, controlled, unconfounded, trials in 
patients with stroke, mild cognitive impairment or dementia, or 
radiological features of SVD, who were randomized to treat-
ment with cilostazol. Control groups received placebo tablets, 
another antiplatelet, or received no cilostazol (open label). We 
excluded trials only published as conference abstracts, where 
translation into English was not possible, or where the full text 
was not available.
We included trials that reported any of the following: 
recurrent stroke (all, ischemic, hemorrhagic), incident demen-
tia, incident mild cognitive impairment, change in cognitive 
test scores including domain specific scores, intracranial 
hemorrhage, other major/fatal bleeding, other systemic 
bleeding complications, death, myocardial infarction, depen-
dency in activities of daily living, symptoms related to cilo-
stazol use (such as nausea, headache, palpitations), change 
in white matter hyperintensities, progression/development 
of lacunes, microbleeds, perivascular spaces, brain atrophy 
(assessed by volume or validated score).
Two reviewers screened titles and abstracts of all identi-
fied articles (G.W. Blair, C. McHutchison), independently per-
formed full text review of relevant papers, extracted data from 
included papers using standardized forms, and cross-checked 
their findings.
We extracted data on trial setting (hospital, community, etc), 
number of participants, sex, inclusion illness, diagnosis method 
including cognitive testing, proportion with lacunar stroke, ran-
domization methods, time from onset of inclusion illness to 
randomization, blinding, treatment dose, duration, control allo-
cation, concomitant antiplatelet or other agents, methods of 
outcome assessment, and proportion of patients with outcomes 
as listed above by intention to treat populations. We assessed 
study quality using the CONSORT (Consolidated Standards of 
Reporting Trials) criteria.7
Discrepancies between the 2 reviewers were resolved 
by discussion and a third reviewer (Dr Wardlaw) who cross-
checked all data extraction.
Meta-Analysis
We entered data into RevMan5 (version 5.3) software package. 
For most analyses, we grouped trials according to (1) their time 
to randomization (randomizing in acute/subacute versus later after 
stroke); and (2) use of other prescribed antiplatelet drug (none, 
cilostazol plus aspirin or clopidogrel versus aspirin or clopidogrel, 
cilostazol versus aspirin or clopidogrel) and meta-analyzed each 
outcome. We meta-analyzed symptoms by type. For death from all 
causes, we assumed no deaths in studies that did not report deaths. 
We used Peto odds ratio (OR) and 95% CIs for the meta-analyses, 
a preferred method where outcome events are infrequent.8
In exploratory sensitivity analyses, we ranked trials accord-
ing to the proportion of patients with small vessel (lacunar) 
ischemic stroke, dichotomized into <40% and ≥40%, or 
unspecified. We also tested time from stroke to start of treat-
ment and other antiplatelet drugs used.
We performed a meta-regression to test whether time to 
start treatment, proportion of patients with lacunar stroke, study 
duration, or comparison antiplatelet agent influenced the effect 
of cilostazol, using R version 3.6.2 (https://cran.r-project.org/) 
meta package.
We assessed risk of bias using funnel plots and heteroge-
neity using I2 and χ2 tests.
RESULTS
We identified 572 articles but excluded 505 after 
abstract screening, and a further 43 after full text review 
(Figure 1). We included 20 unconfounded, original ran-
domized controlled trials, published in 24 papers, includ-
ing 10 505 participants (Table 1).
Characteristics of Included Trials
The 20 trials had a median sample size of 183, range 
20 to 2672. Eighteen trials included patients with stroke 
(n=10 449, Table 1) and 2 included patients with cog-
nitive impairment or dementia of Alzheimer’s type and 
radiological evidence of SVD (n=56).9,10
Of the 18 trials in patients with stroke, 2 only 
included patients with lacunar stroke (n=515),11,12 3 
only included patients with intracranial artery stenosis 
Nonstandard Abbreviations and Acronyms
OR odds ratio
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(n=755),13–15 6 only included patients with noncar-
dioembolic ischemic stroke (n=5264),16–21 most trials 
excluded patients with cardioembolic stroke regard-
less of other inclusion criteria, and one trial included 
patients at high risk of intracerebral hemorrhage 
(n=1534).22 In 9/18 trials, the stroke was lacunar in 
≥40% of participants (n=6943); in the other 9 trials, 
<40% of patients had a lacunar ischemic stroke or the 
subtype proportion was not specified (n=3262).
The time to randomization after diagnosis was <2 
weeks in 8 (n=1940),12,14,15,19–21,23,24 between 2 weeks 
and 6 months in 5 (n=2123),13,18,25–27 and 6 months or 
later in 6 trials (n=6406; including the one trial in cogni-
tive decline/dementia)10,11,16,17,22,28 and was not stated in 
the other trial in cognitive decline.9 The duration of trial 
treatment was 4 weeks in 3 (n=344),19,20,28 10 weeks in 1 
(n=57),11 4 months in 4 (n=1236),12,20,22,23 6 to 8 months 
in 5 (n=753; including both trials in cognitive decline/
dementia),9,10,14,15,18 12 months in 1 (n=68),27 and between 
12 months and 5 years in 6 trials (n=8034).13,16,17,22,25,26
Eight trials used placebo tablets, the rest were open 
label (Table 1). One trial in stroke and one in Alzheimer’s 
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disease tested cilostazol versus control in the absence of 
any other antiplatelet drug; 9 trials tested cilostazol plus 
aspirin or clopidogrel versus aspirin or clopidogrel; 8 trials 
tested cilostazol versus aspirin or clopidogrel, and 1 trial 
tested cilostazol plus aspirin versus clopidogrel plus aspirin.
Of the 18 trials that included patients with stroke, 
one28 did not record recurrent stroke outcomes, and one10 
that included patients with cognitive impairment reported 
recurrent stroke; therefore, 18 trials provided data on 
recurrent stroke (all, ischemic, Table I in the Data Sup-
plement). Sixteen trials reported recurrent hemorrhagic 
stroke, 18 reported death, 3 trials reported cognitive out-
comes (2 trials in patients with cognitive impairment, one 
trial in stroke),9–11 10 trials reported major cardiac out-
comes, 7 assessed functional outcome (modified Rankin 
Scale) but only 5 gave results (precluding meta-analysis 
of effects of cilostazol on dependency), and about half 
the trials reported adverse symptoms (headache, nau-
sea, palpitations, systemic bleeding; Table II in the Data 
Supplement). Outcomes are summarized in Table 2.
Recurrent Ischemic Stroke
Eighteen trials (n=10 225) reported recurrent isch-
emic stroke (cilostazol 5127, control 5098). Cilostazol 
decreased recurrent ischemic stroke (OR=0.68 [95% CI, 
0.57–0.81]; P<0.0001), Figure 2, without heterogene-
ity. Most benefit appeared in the 9 trials testing cilostazol 
started >2 weeks after stroke (median 76 days; omitted 
in 3 trials) and given long term, where the ORs are all 
<1 regardless of comparator group or concomitant anti-
platelet drug use (see sensitivity analyses below). In con-
trast, in the 8 trials starting cilostazol within 2 weeks of 
stroke (median 9.6 days; omitted in 4 trials) and assess-
ing outcome at 1 to 4 months, the ORs all overlapped 
one, although the acute/subacute trials were smaller 
than the later-implementation/longer duration trials. A 
similar effect was seen for any recurrent stroke (18 trials, 
n=10 225, 5127 allocated cilostazol, 5098 allocated con-
trol) where cilostazol decreased the odds of any recurrent 
stroke (OR=0.61 [95% CI, 0.523–0.72]; P<0.00001), 
without heterogeneity (Figure I in the Data Supplement).
Hemorrhagic Stroke
Sixteen trials (n=9736) reported recurrent hemorrhagic 
stroke (cilostazol 4885, control 4851). Overall, cilostazol 
reduced hemorrhagic stroke (OR=0.43 [95% CI, 0.29–
0.64]; P=0.0001), Figure 3, without heterogeneity. The 
pattern of effect was similar to that seen in all stroke and 
ischemic stroke although the reduced sample resulted in 
fewer individually significant results.
Major Adverse Cardiovascular Events
Ten trials reported a composite outcome of major adverse 
cardiovascular events (cilostazol 4470, control 4478). 
Cilostazol decreased major adverse cardiovascular events 
(OR=0.66 [95% CI, 0.57–0.76]; P<0.00001), without het-
erogeneity (Figure II in the Data Supplement). Most ben-
efit occurred in trials testing long-term cilostazol starting 
6 months or more after stroke, where summary ORs are 
<1 regardless of whether cilostazol was compared with 
placebo or aspirin or of concomitant antiplatelet drug use.
Death
Eighteen trials reported death from any cause (cilo-
stazol 5123, control 5742). Overall, cilostazol decreased 
the odds of death (OR=0.64 [95% CI, 0.49–0.83]; 
P=0.0009), Figure III in the Data Supplement, without 
heterogeneity. Most benefit occurred in trials randomiz-
ing patients late after diagnosis while trials randomizing 
soon after stroke were more equivocal.
Cognition
Two trials provided meta-analyzable results (cilostazol 29, 
control 27; Figure IV in the Data Supplement), but data 
were too sparse to draw conclusions. One trial (LACI-1) 
that could not be meta-analyzed reported a mean differ-
ence (adjusted for baseline) in Trail Making Test A of 
−4.0 (−12.7 to 4.7; P=0.37).
Radiological Markers of SVD
Only 3 trials reported SVD imaging markers although 
each reported a different measure (silent infarcts, new 
ischemic lesion, microbleeds). Overall 55/557 partici-
pants allocated cilostazol developed an imaging lesion 
compared with 48/581 allocated control (OR=1.22 
[95% CI, 0.81–1.84]; P=0.34).
Adverse Symptoms
The types of symptoms reported by each study varied 
(Table II in the Data Supplement). In general, patients 
allocated cilostazol had more headache, dizziness, pal-
pitations, tachycardia and diarrhea, but less constipation 
and nonstroke bleeding events (Table 2; Figure V in the 
Data Supplement). There was no heterogeneity for the 
above outcomes apart from systemic bleeding and pal-
pitations (palpitations I2=54%, χ2=19.43, P=0.02; sys-
temic bleeding I2=69%, χ2=25.6, P=0.001).
Sensitivity Analyses
Lacunar Versus Nonlacunar Stroke
In the 8 trials with <40% or unstated proportion of 
patients with lacunar stroke (cilostazol 1639, control 
1623), cilostazol did not reduce recurrent ischemic 
stroke (OR=0.72 [95% CI, 0.49–1.07]; P=0.10, with-
out heterogeneity), Figure VIA in the Data Supplement. 
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Table 1. Characteristics of Included Studies Table 1. Continued
Study and 
Country Where Done
Study Details Cilostazol Group Control Group
Total n
Time From Diagnosis 
to Randomization Treatment Duration Patient Group Stroke Subtype Cilos-tazol n Cilostazol Dose Additional Treatment Control n Control Treatment Control Dose
ARCC28 244 At least 2 wk 
 to ≥365 d
4 wks Ischemic stroke NS 125 100 mg 
bd
Aspirin 100 mg daily 119 Placebo and aspirin Aspirin 100 mg daily
Korea
CAIST23 458 48 h 90 d Ischemic stroke 58% SVD, 28% LA, 1% CE, 
12% other
231 200 mg 
daily
… 227 Aspirin 300 mg daily
Korea
CASID9 36 NS 24 wk Probable Alzheimer Disease with 
white matter lesions
Not applicable 18 100 mg bd (2 wk) then 200 
mg bd
… 18 Placebo NS
Korea
CASISP26 719 1–6 mo Up to 540 d Ischemic stroke NS 360 NS … 359 Aspirin NS
China
CATHARSIS13 163 2 wks to 6 mo 2 y Ischemic stroke, >50% stenosis 
ipsilat intracran ICA or MCA
All non-CE ischemic stroke 83 200 mg daily Aspiring 100 mg daily 80 Aspirin 100 mg daily
Japan
CSPS25 1067 1–6 mo Cil=632.2±467.7 d Ischemic stroke 75% lacunar, 14% 
atherothrombotic 9% mixed, 
2% UK
533 100 mg twice daily … 534 Placebo 100 mg twice daily
Japan Cont=695.1±456.3 d
CSPS216 2672 Up to 26 wks 1–5 y Non-CE ischemic stroke 65% lacunar, 32% 
atherothrombotic, 3% UK
1337 100 mg twice daily … 1335 Aspirin 81 mg daily
Japan
CSPS.com17 1879 8–180 d 6 mo to 3.5 y Non-CE ischemic stroke 49% lacunar, 42% 
atherothrombotic, 9% other/
UK
932 100 mg twice daily Aspirin 81 mg or 100 mg 
daily or Clopidogrel 50 mg 
or 75 mg daily
947 Aspirin or Clopidogrel Aspirim=81 mg or 100 mg daily
Japan Clopidogrel=50 mg or 75 mg daily
ECLIPse12 203 7 d 90 d Lacunar ischemic stroke 100% lacunar 100 100 mg twice daily Aspirin 100 mg daily 103 Placebo and aspirin Placebo=
100 mg twice daily
Aspirin=100 mg dailyKorea
Guo et al27 68 1–6 mo 12 mo Ischaemic stroke NS 34 100 mg twice daily … 34 Aspirin 100 mg daily
China
Johkura et al18 106 1–6 mo 6 mo Non-CE ischemic stroke NS but all supratentorial 57 200 mg daily … 49 Aspirin 100 mg daily
Japan c/o dizziness
LACI-111 57 Up to 4 y Treatment (Cil: 9 wk; 
Cil+ISMN immediate start: 
7 wk; Cil+ISMN delayed: 6 
wk), Control: 11 wk
Lacunar stroke 100% lacunar 42 100 mg twice daily Aspirin 75 mg or  
Clopidogrel 75 mg daily
15 Aspirin or clopidogrel 75 mg daily
UK
Lee et al24 80 Within 7 d 90 d Ischemic stroke or TIA NS 40 100 mg twice daily Placebo Aspirin 40 Placebo and aspirin Placebo=bd
Korea Aspirin=100 mg daily
Nakamura et al19 76 48 h 6 mo Non-CE ischemic stroke 47% SVD, 20% LA atheroma, 
33% other/UK
38 100 mg twice daily Aspirin 300 mg daily (4 d) 
then 100 mg daily
38 Aspirin 300 mg daily (4 d) then 100 mg daily
Japan
Ohnuki et al20 24 Within 1 wk 4 wk Non-CE ischemic stroke 41% lacunar, 25% 
atherothrombotic, 6% other
13 200 mg daily Aspirin 100 mg daily 11 Aspirin 100 mg daily
Japan
PICASSO22 1534 180 d Median=1.9 y  
IQR=1.0–3.0
Ischemic stroke at high  
risk of ICH
Prior ICH or ≥2 microbleeds 766 100 mg bd Aspirin placebo daily 768 Aspirin and placebo Aspirin=100 mg daily
Korea Placebo=bd
Sakurai et al10 20 >6 mo 6 mo Possible Alzheimer Disease and 
SVD lesions
Not applicable 11 100 mg daily  9 Aspirin or Clopidogrel Aspirin=100 mg daily
Japan Clopidogrel=50–75 mg daily
Shimizu 507 24 h 3 mo Non-CE progressing ischemic 
stroke
67% lacunar, 28% 
atherothrombotic, 5% other
251 200 mg daily Aspirin 300 mg daily 256 Aspirin Aspirin 300 mg daily
(Tohoku)21
Japan
TOSS14 135 2 wk 6 mo Ischemic stroke, intracranial  
ICA or MCA stenosis
NS 67 100 mg bd Aspirin 100 mg daily 68 Placebo and aspirin Aspirin 100 mg daily
Korea
TOSS-215 457 2 wk 7 mo Ischemic stroke, intracranial  
ICA or MCA stenosis
NS 232 100 mg bd Aspirin 75–150 mg daily 225 Clopidogrel and aspirin Clopidogrel=75 mg daily
Korea Aspirin=75–150 mg daily
(Continued ) bd indicates twice daily; CAIST, Cilostazol in Acute Stroke Treatment; CASISP, Cilostazol Versus Aspirin for Secondary Ichemic Stroke Prevention; CATHARSIS, 
Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis; CE, cardioembolic; Cil, cilostazol; c/o, complaining of; cont, control; CSPS, 
Cilostazol Stroke Prevention Study; ICA, internal carotid artery; ICH, intracerebral hemorrhage; intracran, intracranial; ipsilat, ipsilateral; IQR, interquartile range; LA, large 
artery; MCA, middle cerebral artery; NS, not stated; PICASSO, Prevention of Cardiovascular Events in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage; 
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Table 1. Characteristics of Included Studies Table 1. Continued
Study and 
Country Where Done
Study Details Cilostazol Group Control Group
Total n
Time From Diagnosis 
to Randomization Treatment Duration Patient Group Stroke Subtype Cilos-tazol n Cilostazol Dose Additional Treatment Control n Control Treatment Control Dose
ARCC28 244 At least 2 wk 
 to ≥365 d
4 wks Ischemic stroke NS 125 100 mg 
bd
Aspirin 100 mg daily 119 Placebo and aspirin Aspirin 100 mg daily
Korea
CAIST23 458 48 h 90 d Ischemic stroke 58% SVD, 28% LA, 1% CE, 
12% other
231 200 mg 
daily
… 227 Aspirin 300 mg daily
Korea
CASID9 36 NS 24 wk Probable Alzheimer Disease with 
white matter lesions
Not applicable 18 100 mg bd (2 wk) then 200 
mg bd
… 18 Placebo NS
Korea
CASISP26 719 1–6 mo Up to 540 d Ischemic stroke NS 360 NS … 359 Aspirin NS
China
CATHARSIS13 163 2 wks to 6 mo 2 y Ischemic stroke, >50% stenosis 
ipsilat intracran ICA or MCA
All non-CE ischemic stroke 83 200 mg daily Aspiring 100 mg daily 80 Aspirin 100 mg daily
Japan
CSPS25 1067 1–6 mo Cil=632.2±467.7 d Ischemic stroke 75% lacunar, 14% 
atherothrombotic 9% mixed, 
2% UK
533 100 mg twice daily … 534 Placebo 100 mg twice daily
Japan Cont=695.1±456.3 d
CSPS216 2672 Up to 26 wks 1–5 y Non-CE ischemic stroke 65% lacunar, 32% 
atherothrombotic, 3% UK
1337 100 mg twice daily … 1335 Aspirin 81 mg daily
Japan
CSPS.com17 1879 8–180 d 6 mo to 3.5 y Non-CE ischemic stroke 49% lacunar, 42% 
atherothrombotic, 9% other/
UK
932 100 mg twice daily Aspirin 81 mg or 100 mg 
daily or Clopidogrel 50 mg 
or 75 mg daily
947 Aspirin or Clopidogrel Aspirim=81 mg or 100 mg daily
Japan Clopidogrel=50 mg or 75 mg daily
ECLIPse12 203 7 d 90 d Lacunar ischemic stroke 100% lacunar 100 100 mg twice daily Aspirin 100 mg daily 103 Placebo and aspirin Placebo=
100 mg twice daily
Aspirin=100 mg dailyKorea
Guo et al27 68 1–6 mo 12 mo Ischaemic stroke NS 34 100 mg twice daily … 34 Aspirin 100 mg daily
China
Johkura et al18 106 1–6 mo 6 mo Non-CE ischemic stroke NS but all supratentorial 57 200 mg daily … 49 Aspirin 100 mg daily
Japan c/o dizziness
LACI-111 57 Up to 4 y Treatment (Cil: 9 wk; 
Cil+ISMN immediate start: 
7 wk; Cil+ISMN delayed: 6 
wk), Control: 11 wk
Lacunar stroke 100% lacunar 42 100 mg twice daily Aspirin 75 mg or  
Clopidogrel 75 mg daily
15 Aspirin or clopidogrel 75 mg daily
UK
Lee et al24 80 Within 7 d 90 d Ischemic stroke or TIA NS 40 100 mg twice daily Placebo Aspirin 40 Placebo and aspirin Placebo=bd
Korea Aspirin=100 mg daily
Nakamura et al19 76 48 h 6 mo Non-CE ischemic stroke 47% SVD, 20% LA atheroma, 
33% other/UK
38 100 mg twice daily Aspirin 300 mg daily (4 d) 
then 100 mg daily
38 Aspirin 300 mg daily (4 d) then 100 mg daily
Japan
Ohnuki et al20 24 Within 1 wk 4 wk Non-CE ischemic stroke 41% lacunar, 25% 
atherothrombotic, 6% other
13 200 mg daily Aspirin 100 mg daily 11 Aspirin 100 mg daily
Japan
PICASSO22 1534 180 d Median=1.9 y  
IQR=1.0–3.0
Ischemic stroke at high  
risk of ICH
Prior ICH or ≥2 microbleeds 766 100 mg bd Aspirin placebo daily 768 Aspirin and placebo Aspirin=100 mg daily
Korea Placebo=bd
Sakurai et al10 20 >6 mo 6 mo Possible Alzheimer Disease and 
SVD lesions
Not applicable 11 100 mg daily  9 Aspirin or Clopidogrel Aspirin=100 mg daily
Japan Clopidogrel=50–75 mg daily
Shimizu 507 24 h 3 mo Non-CE progressing ischemic 
stroke
67% lacunar, 28% 
atherothrombotic, 5% other
251 200 mg daily Aspirin 300 mg daily 256 Aspirin Aspirin 300 mg daily
(Tohoku)21
Japan
TOSS14 135 2 wk 6 mo Ischemic stroke, intracranial  
ICA or MCA stenosis
NS 67 100 mg bd Aspirin 100 mg daily 68 Placebo and aspirin Aspirin 100 mg daily
Korea
TOSS-215 457 2 wk 7 mo Ischemic stroke, intracranial  
ICA or MCA stenosis
NS 232 100 mg bd Aspirin 75–150 mg daily 225 Clopidogrel and aspirin Clopidogrel=75 mg daily
Korea Aspirin=75–150 mg daily
(Continued ) bd indicates twice daily; CAIST, Cilostazol in Acute Stroke Treatment; CASISP, Cilostazol Versus Aspirin for Secondary Ichemic Stroke Prevention; CATHARSIS, 
Cilostazol-Aspirin Therapy Against Recurrent Stroke With Intracranial Artery Stenosis; CE, cardioembolic; Cil, cilostazol; c/o, complaining of; cont, control; CSPS, 
Cilostazol Stroke Prevention Study; ICA, internal carotid artery; ICH, intracerebral hemorrhage; intracran, intracranial; ipsilat, ipsilateral; IQR, interquartile range; LA, large 
artery; MCA, middle cerebral artery; NS, not stated; PICASSO, Prevention of Cardiovascular Events in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage; 
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stroke (cilostazol 3477, control 3466; of which, 6 trials, 
total n=4964, included 58% or more lacunar strokes), 
cilostazol reduced recurrent ischemic stroke (OR=0.64 
[95% CI, 0.52–0.79]; P<0.0001, without heterogeneity). 
However, the effect of cilostazol on recurrent ischemic 
stroke did not differ between the 2 subgroups (<40% 
or ≥40% with lacunar stroke), on formal testing (χ2 
for difference=0.27, P=0.60, I2=0%, P=0.60, without 
heterogeneity).
Time From Stroke to Treatment
Patients allocated treatment within 2 weeks of stroke, 
and where treatment was generally continued for no 
more than 4 months, those allocated cilostazol had 
similar rates of recurrent ischemic stroke (21/972) 
than those allocated control (19/968), OR=1.10 (95% 
CI, 0.58–2.05), P=0.78 without heterogeneity (Figure 
VIB in the Data Supplement). In patients starting treat-
ment beyond 2 weeks after stroke (median), and where 
treatment was generally continued for 6 months to 
5 years, those allocated to cilostazol had fewer recur-
rent ischemic strokes (189/4155) than those allocated 
control (286/4130), OR=0.65 (95% CI, 0.54–0.78), 
P<0.00001, without heterogeneity. However, there was 
no evidence of a between group difference (acute ver-
sus late, χ2 2.47, P=0.12, with moderate heterogeneity, 
I2=59.5%).
Concomitant Antiplatelet Drugs
Trials which randomized between cilostazol and no cilo-
stazol in the absence or presence of concomitant aspi-
rin or clopidogrel showed similar benefit for cilostazol 
(no aspirin, OR=0.51 [95% CI, 0.33–0.79]; P=0.003; all 
patients received aspirin or clopidogrel, OR=0.51 [95% CI, 
0.35–0.74]; P=0.0004) (Figure VIC in the Data Supple-
ment). However, in trials where cilostazol was compared 
with aspirin or clopidogrel, including one trial random-
izing to cilostazol+aspirin versus clopidogrel+aspirin,15 
there was no definite benefit of cilostazol (OR=0.81 
[95% CI, 0.65–1.02]; P=0.08). Across the 3 subgroups, 







n/N Control n/N OR/SMD (95% CI) P Value
Subgroup 
I2 (%) χ2 P Value
All stroke 18 10 225 242/5127 384/5098 0.61 (0.52 to 0.72) <0.00001 33.5 0.18
Ischemic stroke 18 10 225 210/5127 305/5098 0.68 (0.57 to 0.81) <0.00001 44.5 0.11
Hemorrhagic stroke 16 9736 30/4885 72/4851 0.43 (0.29 to 0.64) <0.0001 0 0.55
MACE 10 8948 320/4470 470/4478 0.66 (0.57 to 0.76) <0.00001 2.5 0.39
Death, all cause 18 10 865 93/5123 144/5742 0.64 (0.49 to 0.83) 0.0009 18.0 0.30
Cognition 2 56 80 72 0.03 (−0.29 to 0.35) 0.84 0.0 0
Headache 14 9582 743/4804 413/4779 2.00 (1.76 to 2.28) <0.00001 69 0.0001
Dizziness 9 6837 349/3419 292/3418 1.22 (1.04 to 1.44) 0.02 15 0.31
Palpitations 10 9147 281/4566 124/4581 3.14 (2.57 to 3.84) <0.00001 54 0.02
Tachycardia 5 5396 145/2698 33/2698 3.74 (2.77 to 5.06) <0.00001 43 0.15
Diarrhea 5 4064 303/2434 126/2403 2.21 (1.78 to 2.74) <0.00001 41 0.13
Constipation 3 4664 189/2334 268/2330 0.68 (0.56 to 0.82) 0.0001 0 0.72
Nausea 4 3095 76/1548 53/1547 1.47 (1.02 to 2.11) 0.04 0 0.88
Systemic bleeding 12 8387 79/4211 102/4176 0.73 (0.54 to 0.99) 0.04 69 0.001
Sensitivity analysis: effect on ischemic stroke by subgroup
 Ischemic stroke subtype*: <40% lacunar stroke 8 3262 68/1639 101/1623 0.72 (0.49 to 1.07) 0.10 14 0.32
 ≥40% lacunar stroke 9 6943 142/3477 222/3466 0.64 (0.52 to 0.79) <0.0001 0 0.54
Test for subgroup difference χ2=0.27, P=0.60, I2=0
 Time to treatment*: <2 wks of stroke (9.6 d)† 8 1940 21/972 19/968 1.1 (0.58 to 2.05) 0.78 0 0.81
 ≥2 wk of stroke (76 d)† 10 8285 189/4155 286/4130 0.65 (0.54 to 0.78) <0.0001 0 0.52
Test for subgroup difference χ2=2.47, P=0.12, I2=59.5
 Additional antiplatelet drugs: Cil vs no Cil, 
no antiplatelet
1 1067 30/533 57/534 0.51 (0.33 to 0.79) 0.003 n/a n/a
 Cil+Asp or Clop vs Asp or Clop 8 3044 40/1526 78/1518 0.51 (0.35 to 0.74) 0.0004 0 0.88
 Cil vs Asp or Clop 9 6114 140/3068 170/3046 0.81 (0.65 to 1.02) 0.08 0 0.68
Test for subgroup difference χ2=.31, P=0.04, I2=68.3
Cil indicates cilostazol; MACE, major adverse cardiovascular events; n/a, not applicable; n/N, number of events/total number allocated to that group; OR, odds ratio; 
and SMD, standardized mean difference.
*Comparison is any cilostazol vs no cilostazol.
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there was evidence of between-subgroup differences (χ2, 
6.31; P=0.04), and moderate heterogeneity (I2=68.3%). 
Restricting the analysis to trials comparing cilostazol with 
one antiplatelet drug in the absence of another antiplatelet 
drug by excluding the TOSS2 trial showed benefit of cilo-
stazol over the other antiplatelet drug (OR=0.78 [95% CI, 
Figure 2. Effect of cilostazol on ischemic stroke.
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Figure 3. Effect of cilostazol on hemorrhagic stroke.
CASISP indicates Cilostazol Versus Aspirin for Secondary Ichemic Stroke Prevention; CATHARSIS, Cilostazol-Aspirin Therapy Against Recurrent 
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0.62–0.99]; P=0.04, without heterogeneity) and removed 
the evidence of between-subgroup difference (χ2, 5.19; 
P=0.07), but retained heterogeneity (I2=61.4%).
Meta-Regression
Meta-regression of time to treatment, duration of treat-
ment, and proportion of lacunar strokes, adjusted for 
comparator antiplatelet agent, did not identify any sig-
nificant subgroup effects on outcomes of recurrent isch-
emic or hemorrhagic stroke.
Sources of Bias
The median trial quality was 23.5/37 (minimum 14, max-
imum 35), with methods sections attaining the lowest 
scores on average (Table III and Figure VII in the Data 
Supplement).
Funnel plots on all stroke and ischemic stroke showed 
some skew suggesting reporting bias but not for hemor-
rhagic stroke did not show any skew (Figure VIII in the 
Data Supplement).
DISCUSSION
Cilostazol reduced recurrent stroke, recurrent ischemic 
stroke, recurrent hemorrhagic stroke, death and major 
adverse cardiovascular events compared with control, in 
the presence or absence of aspirin, or when compared 
directly with aspirin (data were limited for comparison 
with clopidogrel). Most benefit occurred in trials that ran-
domized patients at 2 or more weeks after stroke and 
administered cilostazol for at least 6 months or longer, 
without evidence of increased risk with long-term treat-
ment. There were very few data on the effect of cilostazol 
on functional outcome, cognitive decline, or radiologi-
cal markers of SVD. Adverse symptoms such as head-
ache, palpitations, dizziness, and diarrhea were clearly 
increased with cilostazol although, importantly, systemic 
bleeding events were reduced.
The review limitations are related to the available 
data and include variation between trials in antiplatelet 
drug use, times to randomization after stroke, durations 
of treatment, not reporting dependency outcomes, and 
lack of information on stroke subtypes. Included studies 
varied greatly in sample size and some studies had no 
events in either group for certain outcomes. Antiplate-
let therapy has changed since some studies were com-
pleted. Guidelines now advice dual antiplatelets short 
term after transient ischemic attack or minor ischemic 
stroke, followed by clopidogrel longer term. Only one 
study compared cilostazol to clopidogrel and both groups 
also received aspirin.15 Only 2 trials recruited patients 
with cognitive presentations and only one trial in stroke 
assessed cognition. The median trial quality was mod-
erate (23.5/37). Thus, despite the total available data 
from trials of cilostazol totaling over 10 000 patients, the 
conclusions have limitations. There were also strengths 
of the review, including prospective protocol registration, 
assessment of methodological quality, double assess-
ment of papers and data extraction, and careful harmoni-
zation of the trials for analysis.
Cilostazol may have more benefit on several outcomes 
where participants were randomized later after stroke. 
Although arbitrary, the trials naturally dichotomized into 
those randomizing within 2 weeks of stroke and those 
randomizing at >2 weeks after stroke, of which about a 
third randomized between 2 weeks and 6 months and 
2 thirds randomized after 6 months. Trials randomizing 
>6 months after stroke had long durations of treatment 
and follow-up. Thus, the apparent benefit of cilostazol 
in trials randomizing late rather than early may reflect 
the paucity of acute trials, shorter duration of treatment, 
higher proportion of lacunar strokes, or that cilostazol is 
less effective in preventing early recurrent stroke. Similar 
results have been seen with another phosphodiester-
ase inhibitor dipyridamole (PDE5 inhibitor) with mild-
antiplatelet and proendothelial effects,2 which reduced 
stroke recurrence while increasing headache, mostly in 
Western populations. The risk of stroke recurrence varies 
by stroke subtype, atherothromboembolic stroke recur-
rence risk being the highest immediately after transient 
ischemic attack/minor stroke, then declining, whereas 
lacunar stroke has lower risk of early recurrence but the 
rate remains elevated in the longer term.
Cilostazol’s apparent greater benefit late after stroke 
could reflect several possible mechanisms. Weaker anti-
platelet effects3 and hence inferior stroke prevention 
compared with aspirin or clopidogrel early after transient 
ischemic attack/stroke (when stronger antiplatelet activ-
ity may be more beneficial) is supported by the neutral 
effect of cilostazol on ischemic stroke recurrence com-
pared with aspirin or clopidogrel (Figure VIC in the Data 
Supplement). Increasing benefit of cilostazol late after 
stroke was also demonstrated in CASISP, which found 
no difference in recurrent stroke between cilostazol and 
aspirin within 6 months of stroke, but increasing benefit 
of cilostazol versus aspirin thereafter.26 The increased 
benefit of cilostazol later after stroke may reflect that 
its mechanisms of action are more relevant to lacu-
nar stroke where recurrence occurs late, supported by 
increased benefit in trials including more patients with 
lacunar stroke (Figure VIA in the Data Supplement). 
Potential benefits for lacunar stroke include endothelial 
stabilization, improved myelin repair, and better astro-
cyte-to-neuronal energy supply,2,11 all of which may take 
some time to accrue. The lower cerebral and systemic 
hemorrhage risks would also confer benefit over other 
antiplatelet drugs, which typically have higher bleeding 
risk the longer they are given, a reason for early stop-
ping of the SPS3 Trial (dual versus single antiplatelet 
drugs) for lacunar stroke29 and seen in the present meta-
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The PICASSO (PreventIon of CArdiovascular events in 
iSchemic Stroke patients with high risk of cerebral hem-
Orrhage) trial suggests that the benefits of cilostazol 
may extend to reducing recurrent stroke and systemic 
bleeding even in patients at high risk of intracerebral 
hemorrhage.22
More data are needed to overcome the limitations 
of the current data, to determine the effect of cilostazol 
on functional and cognitive outcomes after stroke, and 
on delaying cognitive decline. If the effects of cilostazol 
seen in laboratory models translate to people (myelin 
repair, improved neuronal energy supply, and endothe-
lial stabilization) and help to prevent progression of 
brain injury, then cilostazol might also prevent physi-
cal decline seen in SVD. Future studies should com-
pare cilostazol to modern antiplatelet regimes, stratify 
patients by stroke or cognitive impairment, provide more 
data on cognitive, imaging and functional outcomes, and 
on tolerability and compliance. Several ongoing studies 
address these issues. LACI-2 (ISRCTN 14911850) is 
assessing cilostazol long-term after lacunar ischemic 
stroke in the UK including 1-year cognitive and brain 
magnetic resonance imaging follow-up (target n=400). 
The COMCID trial (Asia-Pacific) is assessing cilo-
stazol’s effects on cognitive function, incident demen-
tia, and hippocampal volumes (NCT02491268). Other 
trials are assessing short-term effects of cilostazol 
on cerebrovascular reactivity (eg, Oxford Hemody-
namic Adaptation to Reduce Pulsatility Trial [OxHARP], 
NCT03855332, target n=76).
Cilostazol shows promise for ischemic stroke preven-
tion, with lower risk of hemorrhagic complications, par-
ticularly long term. Its place in stroke therapy may be 
in chronic secondary prevention rather than the acute 
phase. However, most data are from Asia Pacific coun-
tries where stroke etiologies and other factors may dif-
fer from other world regions, hence the need for more 
data. Despite its encouraging safety profile (lower bleed-
ing risk and death), cilostazol causes several symptoms 
(headache, palpitations, diarrhea, nausea), which may 
limit tolerance, requiring more data to guide future rou-
tine use. It is licenced in Europe and the Americas for 
treatment of symptomatic peripheral vascular disease 
and stroke prevention where other antiplatelet agents 
have failed or are not tolerated. However, more evidence 
is needed before it is used more widely in stroke in rou-
tine practice.
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